Arbutus Biopharma ABUS
$4.02 −$0.05 (-1.23%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $3.98 -1.00%
Open$4.01
Prev close$4.07
Day range$3.97 – $4.09
Volume2.99M
Market cap$616.24M
P/E (TTM)3.6
Dividend yield–
Earnings
Average move on report day±3.5%last 16 reports
Closed higher6 of 1638% of the time
Best reaction+10.1%
Worst reaction-13.7%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2024/Q3 | 6 Nov 2024 | Pre Market | ±13.4% | -1.01% | Within range |
| 2024/Q2 | 1 Aug 2024 | Pre Market | ±16.4% | +1.06% | Within range |
| 2024/Q1 | 2 May 2024 | Pre Market | ±14.4% | -0.37% | Within range |
| 2023/Q4 | 29 Feb 2024 | Pre Market | ±24.3% | -2.78% | Within range |
| 2023/Q3 | 7 Nov 2023 | Pre Market | ±16.0% | -1.60% | Within range |
| 2023/Q2 | 3 Aug 2023 | Pre Market | ±12.0% | -0.96% | Within range |
| 2023/Q1 | 4 May 2023 | Pre Market | ±23.9% | +1.59% | Within range |
| 2022/Q4 | 2 Mar 2023 | Pre Market | ±33.6% | +0.00% | Within range |
| 2022/Q3 | 9 Nov 2022 | Pre Market | ±30.2% | -0.81% | Within range |
| 2022/Q2 | 4 Aug 2022 | Pre Market | ±19.3% | +3.25% | Within range |
| 2022/Q1 | 5 May 2022 | Pre Market | ±18.0% | +2.41% | Within range |
| 2021/Q4 | 3 Mar 2022 | Pre Market | ±24.1% | -4.53% | Within range |
| 2021/Q3 | 4 Nov 2021 | Pre Market | ±22.2% | +0.78% | Within range |
| 2021/Q2 | 5 Aug 2021 | Pre Market | ±25.5% | +10.14% | Within range |
| 2021/Q1 | 5 May 2021 | Pre Market | ±27.3% | -11.11% | Within range |
| 2020/Q4 | 4 Mar 2021 | Pre Market | ±39.6% | -13.74% | Within range |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$299,000.00-43.5% YoY
Operating profit-$10.27M-23.9% YoY
Net profit$59.12M+863.6% YoY
Diluted EPS$0.30+850.0% YoY
Free cash flow$239.81M+4,222.6% YoY
Operating cash flow$239.81M
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Operating margin80.1%
Net margin121.2%
Return on equity269.6%
Return on assets100.6%
Return on invested capital264.0%
Current ratio1.40
Liabilities / assets74.8%
Cash & investments$337.49M
Total debt$0.00
Net cash (debt)$337.49M
Free cash flow / sales121.8%
No comments yet — be the first to weigh in on ABUS.
Sign in to join the discussion.